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Introduction
Increasingly, it has been realized that the treatment of many inherited or acquired circulating protein deficiencies by repetitive injections of the purified or recombinant proteins is clinically less than ideal. [1] [2] [3] In addition to being inconvenient, such a mode of protein therapeutics is usually not cost-efficient, can result in the administration of various impurities, and may not result in physiologically adequate patterns of protein replacement in blood. Growth hormone deficiency in children is an excellent example of one such condition. 3 While the availability of recombinant human growth hormone (rhGH) has alleviated concerns about the coadministration of noxious contaminants with hGH purified from human cadaveric pituitaries, 4 there still exists dissatisfaction with daily rhGH injections. and parotid glands, via a replication-deficient recombinant adenovirus, and observed secretion of h␣1-AT in the serum at levels likely to be useful for many clinical disorders. Although current adenoviral vectors do not permit stable long-term expression of a transgene product due to both their non-integrating nature and their induction of a potent immune response, 11, 12 they are excellent tools for experiments examining a proof of principle. Salivary glands provide an extremely convenient target tissue for in vivo gene transfer. 13 These glands are readily accessible through the oral cavity, via their excretory ducts, without the need for surgical manipulations. Virtually all parenchymal cells in the gland line the ductal system and are potential targets for in vivo gene transfer. 13, 14 Furthermore, salivary gland cells are physiologically endowed with the ability to produce copious amounts of secretory proteins (albeit for exocrine secretion), and thus may prove to be particularly useful for metabolic engineering. 1 The present report provides a fundamental extension of our initial observations concerning the systemic delivery of transgene products from salivary glands. Specifically, we have demonstrated for the first time that a transgene product (hGH), secreted from salivary glands in an endocrine fashion, has systemic biological efficacy.
Results
As described in Materials and methods, we constructed a replication-deficient, recombinant adenovirus encoding hGH, AdCMVhGH (Figure 1) . Initially, to determine if AdCMVhGH could direct the expression of hGH in vitro, we infected SMIE cells, an epithelial cell line derived from the rat submandibular gland. 15 On Northern blot analysis infected SMIE cells transcribed an approximately 900 nt mRNA which hybridized with an hGH probe (not shown). This sized transcript is expected for the mature hGH, including the polyadenylation sequence. 16 Furthermore, infected SMIE cells produced and secreted the hGH protein ( Figure 2 ). As shown in this figure, Western blot analysis of culture medium from infected cells contained an immunopositive band of approximately 22 kDa, the size expected for authentic hGH. Uninfected control SMIE cells expressed neither hGH mRNA (not shown) nor hGH protein ( Figure 2) .
Expression of hGH in vitro in infected SMIE cells was also virus dose-and time-dependent ( Figure 3 ). We infected cells with different multiplicities of infection (MOI) of AdCMVhGH, from 0 to 300, for up to 72 h. As shown in Figure 3 , the concentration of hGH secreted into the culture media typically reached maximal levels after 48 h, for example, approximately 200 ng/ml at a MOI of 3 to approximately 7 g/ml at a MOI of 300. In general, hGH levels decreased approximately 50% between 48 and 72 h. In some experiments, we also examined the polarity of hGH secretion by culturing SMIE cells on collagen-coated polycarbonate filters, a condition in which the cells are able to form a polarized monolayer. 15 The hGH secreted by the SMIE cells is primarily found in the basal side media. The cells were infected with AdCMVhGH at a MOI of 10 and produced approximately 270 ng hGH/3 × 10 6 cells in 24 h. Of this total hGH, 91.5% was detected in the culture medium and approximately 80% of that was found in basal side media (193 versus 54 ng found in the apical media). Less than 10% of the hGH (approximately 23 ng) was associated with the cell layer at this incubation time.
To determine if AdCMVhGH infection could result in the production of functional hGH in vivo, we adminis- 
Figure 3 hGH production in SMIE cells is virus dose-and time-dependent. Cells were not infected, or infected, with AdCMVhGH (MOI = 0-300), and the incubation continued for up to 72 h. The levels of secreted hGH in the medium were detected using a double-antibody luminometric assay method as described in Materials and methods. Data shown are the mean ± s.e.m. for three separate experiments, each measured in triplicate.
tered the virus by retrograde instillation via the submandibular gland's main excretory duct. We also compared the levels of hGH production and their sequelae following delivery via this site to more commonly used sites of gene transfer; ie administering AdCMVhGH by intramuscular injection and intravenous infusion. As shown in Table 1 , 48 h following infection of adult rat submandibular glands with 5 × 10 9 plaque-forming units (p.f.u.) of AdCMVhGH serum levels of hGH were more than 10-fold over background. The average hGH concentration was 16.4 ng/ml, well above therapeutic levels needed in humans. By comparison, following intramuscular injection of AdCMVhGH, serum hGH was approximately 6 ng/ml, while after intravenous infusion (either by tail Additionally, some animals were examined at 72 h for serum hGH levels after AdCMVhGH infection of their submandibular glands. hGH levels remained elevated at this time (control, n = 5, 2.35 ng/ml; vector, n = 7, 21.04 ng/ml; P Ͻ 0.001).
In order to assess if the hGH produced displayed biological activity, we examined serum levels of IGF-1, as well as multiple serum chemistry parameters. IGF levels in control animals were generally comparable with those previously reported, 17 approximately 640 ng/ml. In animals infected with AdCMVhGH via their submandibular gland, serum IGF-1 was increased by approximately 25% to approximately 800 ng/ml. Serum IGF-1 was modestly elevated (approximately 13%) after the recombinant virus was administered by intramuscular injection, although this difference was not statistically significant. After intravenous virus infusion average IGF-1 levels were increased by approximately 50%. In animals studied 72 h after infection of salivary glands, serum IGF-1 levels were approximately 33% higher than those of controls (828 versus 620 ng/ml; P = 0.022). Furthermore, in animals infected with AdCMVhGH via their submandibular glands we detected serum metabolic changes at 48 h after infection, also consistent with systemic activity of the hGH transgene product. As shown in Table 2 , infected animals showed a two-fold elevation in serum triglycerides and an approximately 35% increase in the BUN:creatinine ratio. Several other parameters commonly associated with longer term elevation in GH, eg total protein, glucose, and cholesterol levels ( Table 2) , showed either modest changes or were unchanged at 48 h. Importantly, the serum metabolic profile of animals secreting the transgene product from their salivary glands was quite similar to that seen when hGH gene transfer occurred via the more commonly utilized routes of intramuscular injection or intravenous infusion.
Discussion
We have previously suggested that salivary glands may provide a convenient site for the transfer of genes encoding proteins for systemic use. 10 As a direct test of that suggestion, we conducted the present series of studies. We chose to examine growth hormone production and its systemic secretion for this experimental test because: (1) there are excellent assays and reagents available to measure hGH; (2) current methods for therapeutic correction of growth hormone are considered non-ideal; 3,4 and (3) rodent GH receptors bind, and are activated by, hGH 18 allowing measurement of biological activity. As a tool for testing our hypothesis, we constructed a recombinant adenovirus which was capable of directing the production and secretion of mature hGH in vitro. When used in vivo to infect salivary glands, this virus resulted in supra-therapeutic levels of hGH in rat serum. Furthermore, the hGH produced in vivo displayed biological activity characteristic of fully functional hGH, ie elevations in serum IGF-1 levels and changes in serum chemistry values indicative of anabolic activity. Thus, we directly have shown that gene transfer to salivary glands can result in the production of a macromolecule with systemic biologic utility.
Salivary glands are a novel tissue site considered for gene transfer. Accordingly, in these short-term studies, we compared the systemic efficacy of hGH gene transfer to the submandibular glands with that obtained following AdCMVhGH infection at more traditional sites of gene transfer, ie an intramuscular site and via an intravenous route. Intramuscular injection of AdCMVhGH resulted in the lowest levels of serum hGH of any of the three delivery routes examined here, but levels were still in modest excess of those considered therapeutic in humans. [1] [2] [3] From a number of studies, it appears that transfer of genes to muscle cells results in fairly stable, long-term expression of transgene products, albeit at modest levels likely due to limited, localized cell transduction. 2, 19, 20 Following virus administration intravenously, average serum hGH levels were quite high. The liver and spleen are the primary sites of cellular infection using this route of administration of recombinant adenoviruses, resulting in fairly high efficiencies of transduction. 21 Indeed, the levels of circulating transgene protein product observed following intravenous adenovirus administration can be in the microgram/ml levels. 22 Our findings are in keeping with such past reports and are in gross excess of the required therapeutic hGH levels in patients. Significantly, and with the caveat that we conducted only short-term experiments, the studies compar-ing hGH expression from different sites of tissue transduction showed that the metabolic response of adult rats following hGH gene transfer to salivary glands was quite similar to that seen after gene transfer intramuscularly or intravenously.
Recombinant adenoviruses have proved to be extremely valuable tools for in vivo gene transfer to establish a point of principle 11 and their use in this study has led to the establishment of such a point. However, particularly because they induce a potent immune response, 12 adenoviral cellular transductions in vivo are short-lived. Hence, while the approach used here establishes the feasibility of using salivary glands for delivery of functional therapeutic proteins systemically, our reliance on first-generation adenoviral vectors makes it clinically impractical at present. None the less, recent dramatic improvements in vector technology 23 suggest that in the near future, longer lived, non-(or less) immunogenic adenovirus-mediated gene transfer will be feasible. Many other methods have been described in attempts to develop practical means of stable systemic therapeutic protein delivery, including the use of a variety of re-engineered and implanted cells 5, [7] [8] for growth hormone. None of these has, as yet, been of practical therapeutic value. It is likely that as improved and novel methods for in vivo gene transfer develop, no single tissue site or transduction method will be recognized as ideal for all clinical applications. Rather different sites and methods will likely be used for specific purposes.
The advantages to considering salivary glands as a potential target site for systemic delivery of endocrine hormones such as GH or other therapeutic proteins include: (1) its easy access without requiring anesthesia; (2) its encapsulation and localized delivery limiting accidental exposure of other tissues, 10 and (3) its basic function as a site for the synthesis and production of proteins for export. The results of the present study, using hGH gene transfer, demonstrate for the first time the validity of this approach for the production of biologically active, systemically required proteins.
Materials and methods
Cell culture and animals Human 293 cells, derived from embryonic kidney, and SMIE cells derived from adult rat submandibular gland, 24 were grown in Eagle's minimum essential medium (EMEM) and in Dulbecco's modified Eagle's medium (DMEM), respectively, supplemented with 10% fetal bovine serum, 2 mm glutamine, 100 units/ml penicillin and 10 g/ml streptomycin. Wistar-derived rats (HarlanSprague-Dawley, Indianapolis, IN, USA; 250-300 g), were used for in vivo experiments. Animals were allowed water and food ad libitum throughout the study.
Adenovirus construction
The hGH structural gene sequences (2.1 kb) present in the plasmid pOGH (obtained from Nichols Institute, San Juan Capistrano, CA, USA) contained the coding sequences of both the signal peptide and the mature hGH, the four intervening introns, and 3Ј noncoding sequences. For construction of the recombinant adenovirus, the 2.1 kb hGH gene sequences were subcloned, as a BamHI-EcoRI fragment, into the pACCMVpLpA vector (a gift from Dr C Newgard, University of Texas Southwestern Medical Center, Dallas, TX, USA). The resulting plasmid was subjected to DNA sequencing to confirm the nucleotide sequences in the two joining regions, and then cotransfected with pJM17 (a gift from Dr F Graham, McMaster University, Hamilton, Ontario, Canada) into 293 cells as previously described. 25, 26 The recombinant adenovirus so generated (termed AdCMVhGH) was plaque-purified.
In In vivo gene transfer Anesthesia for the in vivo gene transfer was performed exactly as described. 10, 13 Each rat received 5 × 10 9 p.f.u. of AdCMVhGH in 50 l aliquots either by intramuscular injection (quadriceps), intravenous infusion (tail vein or femoral vein; with similar results) or by submandibular duct cannulation. Control animals received vehicle administered by intravenous infusion only. All animals received 1 mg of dexamethasone at the time of gene transfer (intramuscularly) and each day until death. 27 At the end of the experiments, animals were anesthetized and blood samples obtained by cardiac puncture. Serum samples were analyzed as described below.
Serum chemistries
The concentration of hGH in samples was measured by a double antibody chemiluminescence assay according to the instruction of the manufacturer (Nichols Institute). Rat IGF-1 was measured by radioimmunossay (Endocrine Sciences, Calabasas Hills, CA, USA) and routine serum chemistry parameters were assessed (ANTEC Diagnostics, Farmingdale, NY, USA).
Statistical analyses
Results obtained from in vivo experiments were tested for statistical significance using a t test (for parametric data) or a Mann-Whitney U test (for non-parametric data).
